Selected research
Industry Research
Lung Cancer Diagnostic And Screening Industry Research Report 2026
Market perspective
The global Lung Cancer Diagnostic And Screening market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Lung Cancer Diagnostic And Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Lung Cancer Diagnostic And Screening market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Lung Cancer Diagnostic And Screening market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Lung Cancer Diagnostic And Screening include Pfizer, F.Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific, AstraZeneca Plc, Abbott Laboratories, Medtronic Plc, Danaher Corporation and Siemens Healthcare GmbH, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Lung Cancer Diagnostic And Screening market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Lung Cancer Diagnostic And Screening.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lung Cancer Diagnostic And Screening Market by Company
Pfizer
F.Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Thermo Fisher Scientific
AstraZeneca Plc
Abbott Laboratories
Medtronic Plc
Danaher Corporation
Siemens Healthcare GmbH
FUJIFILM Corporation
KoninklijikePhilips N.V.
GE Healthcare Bio Sciences AB
Quest Diagnostics lIncorporated
Agilent Technologies lnc
Qiagen Inc.
Myriad Genetic Laboratories Inc.
NeoGenomics Laboratories Inc
Canon MedicalSystems Corporation
Eon Health Inc
Lung Cancer Diagnostic And Screening Segment by Type
Instrument
Consumables and Accessories
Lung Cancer Diagnostic And Screening Segment by Application
Hospital
Independent Diagnostic Laboratory
Lung Cancer Diagnostic And Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Diagnostic And Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Diagnostic And Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Diagnostic And Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Lung Cancer Diagnostic And Screening companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Instrument
- Consumables and Accessories
Applications
- Hospital
- Independent Diagnostic Laboratory
Companies covered
- Pfizer
- F.Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Thermo Fisher Scientific
- AstraZeneca Plc
- Abbott Laboratories
- Medtronic Plc
- Danaher Corporation
- Siemens Healthcare GmbH
- FUJIFILM Corporation
- KoninklijikePhilips N.V.
- GE Healthcare Bio Sciences AB
- Quest Diagnostics lIncorporated
- Agilent Technologies lnc
- Qiagen Inc.
- Myriad Genetic Laboratories Inc.
- NeoGenomics Laboratories Inc
- Canon MedicalSystems Corporation
- Eon Health Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Lung Cancer Diagnostic And Screening by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Instrument
- 2.2.3 Consumables and Accessories
- 2.3 Lung Cancer Diagnostic And Screening by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Independent Diagnostic Laboratory
- 2.4 Assumptions and Limitations
3 Lung Cancer Diagnostic And Screening Breakdown Data by Type
- 3.1 Global Lung Cancer Diagnostic And Screening Historic Market Size by Type (2021-2026)
- 3.2 Global Lung Cancer Diagnostic And Screening Forecasted Market Size by Type (2027-2032)
4 Lung Cancer Diagnostic And Screening Breakdown Data by Application
- 4.1 Global Lung Cancer Diagnostic And Screening Historic Market Size by Application (2021-2026)
- 4.2 Global Lung Cancer Diagnostic And Screening Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Lung Cancer Diagnostic And Screening Market Perspective (2021-2032)
- 5.2 Global Lung Cancer Diagnostic And Screening Growth Trends by Region
- 5.2.1 Global Lung Cancer Diagnostic And Screening Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Lung Cancer Diagnostic And Screening Historic Market Size by Region (2021-2026)
- 5.2.3 Lung Cancer Diagnostic And Screening Forecasted Market Size by Region (2027-2032)
- 5.3 Lung Cancer Diagnostic And Screening Market Dynamics
- 5.3.1 Lung Cancer Diagnostic And Screening Industry Trends
- 5.3.2 Lung Cancer Diagnostic And Screening Market Drivers
- 5.3.3 Lung Cancer Diagnostic And Screening Market Challenges
- 5.3.4 Lung Cancer Diagnostic And Screening Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Lung Cancer Diagnostic And Screening Players by Revenue
- 6.1.1 Global Top Lung Cancer Diagnostic And Screening Players by Revenue (2021-2026)
- 6.1.2 Global Lung Cancer Diagnostic And Screening Revenue Market Share by Players (2021-2026)
- 6.2 Global Lung Cancer Diagnostic And Screening Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Lung Cancer Diagnostic And Screening Head Office and Area Served
- 6.4 Global Lung Cancer Diagnostic And Screening Players, Product Type & Application
- 6.5 Global Lung Cancer Diagnostic And Screening Manufacturers Established Date
- 6.6 Global Lung Cancer Diagnostic And Screening Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Lung Cancer Diagnostic And Screening Market Size (2021-2032)
- 7.2 North America Lung Cancer Diagnostic And Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 7.4 North America Lung Cancer Diagnostic And Screening Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Lung Cancer Diagnostic And Screening Market Size (2021-2032)
- 8.2 Europe Lung Cancer Diagnostic And Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 8.4 Europe Lung Cancer Diagnostic And Screening Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size (2021-2032)
- 9.2 Asia-Pacific Lung Cancer Diagnostic And Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Lung Cancer Diagnostic And Screening Market Size (2021-2032)
- 10.2 South America Lung Cancer Diagnostic And Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 10.4 South America Lung Cancer Diagnostic And Screening Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Lung Cancer Diagnostic And Screening Market Size (2021-2032)
- 11.2 Middle East & Africa Lung Cancer Diagnostic And Screening Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Lung Cancer Diagnostic And Screening Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer
- 12.1.1 Pfizer Company Information
- 12.1.2 Pfizer Business Overview
- 12.1.3 Pfizer Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.1.4 Pfizer Lung Cancer Diagnostic And Screening Product Portfolio
- 12.1.5 Pfizer Recent Developments
- 12.2 F.Hoffmann-La Roche AG
- 12.2.1 F.Hoffmann-La Roche AG Company Information
- 12.2.2 F.Hoffmann-La Roche AG Business Overview
- 12.2.3 F.Hoffmann-La Roche AG Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.2.4 F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Product Portfolio
- 12.2.5 F.Hoffmann-La Roche AG Recent Developments
- 12.3 Bristol-Myers Squibb Company
- 12.3.1 Bristol-Myers Squibb Company Company Information
- 12.3.2 Bristol-Myers Squibb Company Business Overview
- 12.3.3 Bristol-Myers Squibb Company Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.3.4 Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Product Portfolio
- 12.3.5 Bristol-Myers Squibb Company Recent Developments
- 12.4 Thermo Fisher Scientific
- 12.4.1 Thermo Fisher Scientific Company Information
- 12.4.2 Thermo Fisher Scientific Business Overview
- 12.4.3 Thermo Fisher Scientific Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.4.4 Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Product Portfolio
- 12.4.5 Thermo Fisher Scientific Recent Developments
- 12.5 AstraZeneca Plc
- 12.5.1 AstraZeneca Plc Company Information
- 12.5.2 AstraZeneca Plc Business Overview
- 12.5.3 AstraZeneca Plc Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.5.4 AstraZeneca Plc Lung Cancer Diagnostic And Screening Product Portfolio
- 12.5.5 AstraZeneca Plc Recent Developments
- 12.6 Abbott Laboratories
- 12.6.1 Abbott Laboratories Company Information
- 12.6.2 Abbott Laboratories Business Overview
- 12.6.3 Abbott Laboratories Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.6.4 Abbott Laboratories Lung Cancer Diagnostic And Screening Product Portfolio
- 12.6.5 Abbott Laboratories Recent Developments
- 12.7 Medtronic Plc
- 12.7.1 Medtronic Plc Company Information
- 12.7.2 Medtronic Plc Business Overview
- 12.7.3 Medtronic Plc Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.7.4 Medtronic Plc Lung Cancer Diagnostic And Screening Product Portfolio
- 12.7.5 Medtronic Plc Recent Developments
- 12.8 Danaher Corporation
- 12.8.1 Danaher Corporation Company Information
- 12.8.2 Danaher Corporation Business Overview
- 12.8.3 Danaher Corporation Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.8.4 Danaher Corporation Lung Cancer Diagnostic And Screening Product Portfolio
- 12.8.5 Danaher Corporation Recent Developments
- 12.9 Siemens Healthcare GmbH
- 12.9.1 Siemens Healthcare GmbH Company Information
- 12.9.2 Siemens Healthcare GmbH Business Overview
- 12.9.3 Siemens Healthcare GmbH Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.9.4 Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Product Portfolio
- 12.9.5 Siemens Healthcare GmbH Recent Developments
- 12.10 FUJIFILM Corporation
- 12.10.1 FUJIFILM Corporation Company Information
- 12.10.2 FUJIFILM Corporation Business Overview
- 12.10.3 FUJIFILM Corporation Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.10.4 FUJIFILM Corporation Lung Cancer Diagnostic And Screening Product Portfolio
- 12.10.5 FUJIFILM Corporation Recent Developments
- 12.11 KoninklijikePhilips N.V.
- 12.11.1 KoninklijikePhilips N.V. Company Information
- 12.11.2 KoninklijikePhilips N.V. Business Overview
- 12.11.3 KoninklijikePhilips N.V. Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.11.4 KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Product Portfolio
- 12.11.5 KoninklijikePhilips N.V. Recent Developments
- 12.12 GE Healthcare Bio Sciences AB
- 12.12.1 GE Healthcare Bio Sciences AB Company Information
- 12.12.2 GE Healthcare Bio Sciences AB Business Overview
- 12.12.3 GE Healthcare Bio Sciences AB Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.12.4 GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Product Portfolio
- 12.12.5 GE Healthcare Bio Sciences AB Recent Developments
- 12.13 Quest Diagnostics lIncorporated
- 12.13.1 Quest Diagnostics lIncorporated Company Information
- 12.13.2 Quest Diagnostics lIncorporated Business Overview
- 12.13.3 Quest Diagnostics lIncorporated Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.13.4 Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Product Portfolio
- 12.13.5 Quest Diagnostics lIncorporated Recent Developments
- 12.14 Agilent Technologies lnc
- 12.14.1 Agilent Technologies lnc Company Information
- 12.14.2 Agilent Technologies lnc Business Overview
- 12.14.3 Agilent Technologies lnc Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.14.4 Agilent Technologies lnc Lung Cancer Diagnostic And Screening Product Portfolio
- 12.14.5 Agilent Technologies lnc Recent Developments
- 12.15 Qiagen Inc.
- 12.15.1 Qiagen Inc. Company Information
- 12.15.2 Qiagen Inc. Business Overview
- 12.15.3 Qiagen Inc. Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.15.4 Qiagen Inc. Lung Cancer Diagnostic And Screening Product Portfolio
- 12.15.5 Qiagen Inc. Recent Developments
- 12.16 Myriad Genetic Laboratories Inc.
- 12.16.1 Myriad Genetic Laboratories Inc. Company Information
- 12.16.2 Myriad Genetic Laboratories Inc. Business Overview
- 12.16.3 Myriad Genetic Laboratories Inc. Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.16.4 Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Product Portfolio
- 12.16.5 Myriad Genetic Laboratories Inc. Recent Developments
- 12.17 NeoGenomics Laboratories Inc
- 12.17.1 NeoGenomics Laboratories Inc Company Information
- 12.17.2 NeoGenomics Laboratories Inc Business Overview
- 12.17.3 NeoGenomics Laboratories Inc Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.17.4 NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Product Portfolio
- 12.17.5 NeoGenomics Laboratories Inc Recent Developments
- 12.18 Canon MedicalSystems Corporation
- 12.18.1 Canon MedicalSystems Corporation Company Information
- 12.18.2 Canon MedicalSystems Corporation Business Overview
- 12.18.3 Canon MedicalSystems Corporation Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.18.4 Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Product Portfolio
- 12.18.5 Canon MedicalSystems Corporation Recent Developments
- 12.19 Eon Health Inc
- 12.19.1 Eon Health Inc Company Information
- 12.19.2 Eon Health Inc Business Overview
- 12.19.3 Eon Health Inc Revenue in Lung Cancer Diagnostic And Screening Business (2021-2026)
- 12.19.4 Eon Health Inc Lung Cancer Diagnostic And Screening Product Portfolio
- 12.19.5 Eon Health Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst